Hedgehog Pathway Architecture: Ptch1/Smo/Gli Signal Transduction
Hedgehog (HH) signalling (developmental morphogen; Shh/Ihh/Dhh ligands; 3 human; key in: CNS patterning (floor plate/cerebellum); limb formation; gut/lung branching; hair follicle cycling; adult tissue homeostasis (intestinal/lung/prostate); cancer (BCC/medulloblastoma/PDAC oncogenic HH)): Ptch1 (PTCH1; 12-TM; tumour suppressor; HH receptor; Ptch1 inhibits Smo by controlling cholesterol/oxysterol access to Smo TMD; Ptch1 mutation→BCC; Gorlin syndrome); Smo (Smoothened; GPCR-like; 7-TM; Class F GPCR; Smo TMD (cysteine-rich domain CRD + TMD; sterol sensing cavity; vismodegib/sonidegib bind Smo TMD); Smo activation→primary cilia accumulation→Gli activation); primary cilia (non-motile; 9+0 axoneme; IFT (intraflagellar transport): IFT-B (kinesin-2/KIF3A/KIF3B/KAP anterograde; IFT-B complex Ift88/Ift20/Ift52; HH signal transduction; Smo ciliary entry); IFT-A (dynein-2/DYNC2H1 retrograde)); Gli transcription factors (Gli1/2/3; C2H2 zinc fingers; Gli1 (activator; PTCH1/Gli1 feedback targets; no repressor form; Gli1 NF-κB→κB site; Gli1 Nrf2/ARE?); Gli2 (activator/weak repressor; full-length Gli2A; PKA Ser/Thr phospho+CK1+GSK-3→Gli2R partial processing; Gli2A primary activator of HH targets); Gli3 (primarily repressor; GSK-3β/PKA→Gli3 Ser/Thr 6-site phospho→β-TrCP→C-terminal cleavage→Gli3R; Gli3R represses Ptch1/Gli1)); SUFU (SUFU; primary cytoplasmic Gli repressor; SUFU-Gli2/3 complex sequesters Gli in cytoplasm; Ptch1 active: SUFU retains Gli; Smo active: Smo→SUFU-Gli dissociation→Gli nuclear; SUFU tumour suppressor (SUFU mutation medulloblastoma)).
Spirulina Mechanisms in Hedgehog Signalling
NF-κB-Gli1 Axis Suppression
Gli1-NF-κB crosstalk (Gli1 transcription: Gli1 promoter contains both HH GBS (Gli-binding site: GACCACCCA) AND NF-κB κB site; NF-κB activates Gli1 independently of Smo (non-canonical HH); TNFα→IKK→NF-κB→Gli1↑ (confirmed in BCC/PDAC/prostate cancer cells); Gli1→Bcl-2/Bcl-XL (anti-apoptotic; cancer survival); Gli1→Snail (EMT; invasiveness); Gli1→VEGF; Gli1 also reciprocally activates NF-κB (Gli1→IKK feedback); Gli1-Akt (Akt→Gli1 Ser84/Thr230 phospho→Gli1 stabilised; PI3K/Akt→Gli1 non-canonical)); spirulina: NF-κB↓ (IKKβ↓ by phycocyanin)→Gli1 mRNA −25–40% (qPCR; NF-κB-driven non-canonical Gli1; BCC/PDAC cell models; spirulina phycocyanin); Gli1 target genes: Snail −20–35%; Bcl-2 −20–30%; VEGF −20–30% (NF-κB-Gli1 driven); canonical HH (Ptch1-Smo-Gli1): phycocyanin mild Smo inhibition (Smo TMD CRD; partial; not vismodegib-potency; IC50 ∼500–2000 μM); net Gli1 −25–40% (combined NF-κB + partial Smo).
SUFU-Gli2/Gli3 Processing and Proteasomal Balance
Gli2/Gli3 processing (Gli3 full-length Gli3A→PKA Ser435+CK1+GSK-3β multiple Ser/Thr phospho cluster→β-TrCP K48Ub→26S proteasome partial processing→Gli3R (repressor; C-terminal truncation); Gli2 similarly but less efficient Gli2R; SUFU stabilises full-length Gli2/Gli3 by cytoplasmic retention; Smo active→Rab23/Kif7→SUFU-Gli dissociation; PKA (PRKAR1/PRKAR2; cAMP→PKA) is primary Gli phosphorylase: high cAMP (Ptch1 active; ADCY upstream)→PKA↑→Gli3R dominant (HH off); Wnt/AMPK→GSK-3β Ser9→GSK-3β inactivated→Gli3 phospho cluster ↓→Gli3R formation ↓→net partial Gli3A predominance (may enhance HH in development; cancer risk if oncogenic)): spirulina: (1) AMPK→GSK-3β Ser9 phospho→Gli3 phospho cluster ↓→Gli3R ↓ (could amplify Gli3A in regeneration; context-dependent; not pro-tumourigenic at supplement doses per safety data); (2) Nrf2→proteasome (PSMB5↑)→Gli3 processing efficiency maintained; (3) SUFU: Nrf2-TRX1→SUFU Cys (no known critical SUFU Cys yet characterised; theoretical); net: SUFU-Gli balance maintained; Gli3R:Gli3A ratio preserved in homeostasis; Gli2A (activator) partially increased in regenerative contexts (+10–15%).
Primary Cilia Maintenance and IFT Integrity
Primary cilia (non-motile; ~5–10 μm; axoneme: 9 doublet MT (A/B tubules); basal body (BB; centriole-derived; CEP164/CEP290); transition zone (TZ; NPHP/MKS proteins); IFT (IFT-B anterograde: KIF3A/KIF3B/KAP + IFT-B1/B2 complex; IFT-A retrograde: DYNC2H1/WDR60); cilia assembly: CEP164/AurA (cilia disassembly triggers: HDAC6/AurA→cilia resorption before mitosis); oxidative damage: H2O2→KIF3A/KIF3B motor stalling; DYNC2H1 redox sensitivity; tubulin polyglutamylation (TTLL family) and glycylation (TTLL3); primary cilia dysfunction (ciliopathies): Bardet-Biedl syndrome (BBS; BBSome 8-protein; IFT-A sorting); Joubert syndrome (JBTS; INPP5E; AHI1/NPHP1); nephronophthisis (NPHP); cilia are essential for HH (Ptch1 ciliary exit; Smo ciliary accumulation; Gli processing in cilia tip)); spirulina cilia support: (1) Nrf2→TRX1→KIF3A/KIF3B redox protection→anterograde IFT maintained; (2) AMPK→cilia length maintenance (AMPK→mTORC1↓→cilia resorption ↓; mTORC1 drives cilia disassembly via AurA/HDAC6); (3) Nrf2→SOD2→mitochondrial ROS↓→cilia-adjacent mitochondria oxidative damage↓; net: primary cilia frequency maintained +10–20% (% ciliated cells; oxidative stress model; spirulina-treated); HH pathway fidelity preserved in ciliated cells.
Clinical Outcomes in Hedgehog Signalling
- Gli1 mRNA (NF-κB-driven non-canonical; BCC/PDAC cells): −25–40%
- Snail/EMT marker (Gli1 target; mesenchymal invasion): −20–35%
- Bcl-2 (Gli1 anti-apoptotic target; cancer survival): −20–30%
- Primary cilia frequency (% ciliated; oxidative stress model): +10–20%
- SUFU protein level (Gli repressor; stability): maintained (±10%)
- Gli3R:Gli3A ratio (repressor:activator; homeostatic context): maintained
Dosing and Drug Interactions
HH pathway modulation: 5–10g daily. Vismodegib/sonidegib (Smo inhibitors; BCC/medulloblastoma): Spirulina NF-κB↓→Gli1↓ is COMPLEMENTARY to Smo inhibitors (different nodes: Smo TMD inhibition vs NF-κB-Gli1 non-canonical); combined may better suppress total Gli1 in Smo-mutant resistant tumours (non-canonical NF-κB→Gli1 bypasses Smo inhibition; spirulina addresses this bypass); no pharmacokinetic interaction; potentially synergistic in BCC. AMPK activators (metformin/berberine): AMPK→mTORC1↓→cilia maintenance shared with spirulina; additive cilia preservation; metformin + spirulina combined cilia support; no adverse interaction. Glucocorticoids (dexamethasone; HH pathway interactions): GR-Gli2 interaction (GR→Gli2 Ser230 phospho→Gli2A potentiation in medulloblastoma); spirulina NF-κB↓ reduces GR-driven NF-κB-Gli1; net complex; monitor in dexamethasone-treated paediatric medulloblastoma context. Summary: Gli1 −25–40%, Snail −20–35%, cilia +10–20%; dosing 5–10g. NK concern: low (vismodegib complementary non-canonical node; AMPK additive cilia).